Xencor | XNCR - Cash And Equivalent


Xencor reported $44.66M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
Arrowhead Research USD 19.68M 127.85M Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Cytokinetics USD 255.27M 125.43M Jun/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
J&J USD 20.42B 1.27B Jun/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
MacroGenics USD 113.91M 47.39M Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Novartis USD 7.62B 739M Jun/2026
Pfizer USD 976M 727M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Xencor USD 44.66M 30.49M Jun/2026